CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Sustained-release axitinib hydrogel shows promising efficacy and safety in wet age-related macular degeneration and diabetic retinopathy, setting foundation …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Once-monthly subcutaneous treatment offers new option for preventing hereditary angioedema attacks across all patient types from therapy initiation.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
Early Access Program data supports robust efficacy and safety, reinforcing results from the pivotal ARES trial and strengthening …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
Already a subscriber? Log in